ResMed Inc. (RMD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

The Roarable RQD rating is 86, graded A, with the verdict "Roarable Strong Buy — Excellent Cash & Whale Support." the five pillars score as follows: Fundamental Cash Engine 19/20 (ROIC 22.9%; FCF yield 4.67%), Whale 13F Flow 17/20 (institutional accumulation and options positioning), Insider Conviction 17/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 15/20 (beta 0.93; sector sensitivity), and Forensic Balance Sheet 18/20 (Altman Z 12.49; Piotroski F 9/9; Debt/Equity 0.15). For a prospective investor, the strongest support comes from cash generation and balance-sheet quality, which the rating treats as the highest-weighted evidence. The lowest-scoring pillar is macro regime fit, which indicates the stock's sensitivity to sector and market conditions is less favorable than its internal fundamentals. Valuation is a tradeoff: per the Snapshot data, the stock trades at 25.4x trailing earnings and 23.6x forward earnings, so the rating's cash-quality support must be weighed against a multiple that is not low. The rating is a structured summary of the source data and does not constitute personalized financial advice.

ResMed Inc. Is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry. It operates with a market capitalization of $35.6B. The relevant clinical context is obstructive sleep apnea (OSA), where positive-airway-pressure devices and masks are the established treatment category. Specific product lines, customer segments, and revenue mix by product are —

Per the market data, gross margin is 59.4%, operating margin 32.7%, and net margin 27.2%, with ROIC of 22.9%. The Altman Z-Score is 12.49 and the Piotroski F-Score is 9/9, with Debt/Equity of 0.15. Revenue and net income rose across the three reported periods, and FY 2025 free cash flow was $1.66B. The FY 2023 debt figure ($4.58B) is markedly higher than the FY 2024 and FY 2025 figures and is not explained in the source data.

• 🐂 Primary Bull Case: Cash engine and balance sheet score highest in the RQD rating, with ROIC of 22.9% and a Piotroski F-Score of 9/9. With Fundamental Cash Engine at 19/20 (ROIC 22.9%, FCF yield 4.67%) and Institutional Whale Flow at 10/20, sustained execution supports upside toward the top of the $180.27 – $277.67 52-week range.
• 🐻 Primary Bear Case: A GLP-1 OSA therapy (Zepbound) is flagged as a potential headwind to CPAP demand, and valuation at 25.4x trailing earnings leaves limited margin for error. Investors must weigh 25.4x trailing P/E and 19.9x EV/EBITDA against 32.7% operating margins and a 0.93 macro beta if sector demand softens.

The supply-chain classification is "NONE," so upstream and downstream supplier and customer dependencies are — The only recorded ripple is the LLY-to-RMD headwind described above, which is an analyst hypothesis rather than a confirmed effect. The exposure magnitude is undisclosed and is noted as cited in the RMD 10-K. Investors should watch whether OSA prescription trends and CPAP re-supply revenue diverge from the GLP-1 adoption curve, and whether the discontinuation rate constrains the substitution effect over time. Sector correlation data is —

• Key Question #1: What is the company's revenue split by product line and customer segment, and how much is device versus mask re-supply?
• Key Question #2: What is the undisclosed exposure estimate cited in the 10-K for GLP-1 substitution, and what is the observed OSA script trend?
• Key Question #3: Why does FY 2023 debt ($4.58B) differ so sharply from FY 2024 and FY 2025, and what does the reported cash balance look like for FY 2023?